[Diagnosis characteristics features in breast cancer].

Chirurgia (Bucur)

Clinica I Chirurgie Generală-UMF Craiova.

Published: August 2004

Representing about 20% of all woman's cancers in all the world, breast cancer is a multifactorial disease with unknown mechanism facts which may explain the significant growth of incidence and mortality in the last few years. In the absence of screening program in majority cases the diagnosis is discovered too late. In this present study we have made a retrospective study on 487 patients during 1996-2000 at the 1st Surgical Clinic from Craiova. The purpose of this study was the defining of the population with an increased risk which has to be monitorized. In order to accomplish it, we have carefully supervised some of clinical parameters: sex, age, social environment, physiological and pathological antecedents, heredocolateral antecedents, and the constitutional type. The study method was the comparative analysis, and the evaluation according to the modern statistical methods. The risk factors, which can be surely used in defining the groups of population with an increased risk, which should be supervised for an active discover of breast cancer, as the resulted from our study, are: the age decades V, VI, and VII with maximum incidence in subgroups 45-49 and 60-64 years old; early monarch (67.15%); delayed menopause, over 50 years old (84.4%); long exposure to sexual hormones during the reproductive period (the period of menstrual cyclicity over 32 years old); the pathology of the benign tumor, the biggest risk belonging to the proliferative tumours (intraductal papiloma); hyperestrogenism. The only improving method of the therapeutical results in breast cancer is an early discover of it, which can be accomplished only by the implementation of a national program of active discover, in which the essential part belongs to the primary care helped by a widely-broadcast medical education.

Download full-text PDF

Source

Publication Analysis

Top Keywords

breast cancer
12
population increased
8
increased risk
8
active discover
8
study
5
[diagnosis characteristics
4
characteristics features
4
breast
4
features breast
4
breast cancer]
4

Similar Publications

Importance: Endocrine treatments, such as Tamoxifen (TAM) and/or Aromatase inhibitors (AI), are the adjuvant therapy of choice for hormone-receptor positive breast cancer. These agents are associated with menopausal symptoms, adversely affecting drug compliance. Topical estrogen (TE) has been proposed for symptom management, given its' local application and presumed reduced bioavailability, however its oncological safety remains uncertain.

View Article and Find Full Text PDF

Detectability of Al18F-NOTA-HER2-BCH PET for Nodal Metastases in Patients With HER2-Positive Breast Cancer.

Clin Nucl Med

January 2025

From the Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine; Peking University Cancer Hospital and Institute, Beijing, China.

Purpose: The aim of this study was to compare Al18F-NOTA-HER2-BCH and 18F-FDG for detecting nodal metastases in patients with HER2-positive breast cancer on PET/CT.

Patients And Methods: In this retrospective study, 62 participants with HER2-positive breast cancer underwent both Al18F-NOTA-HER2-BCH and 18F-FDG PET/CT. Participants were pathologically confirmed as HER2-positive (IHC 3+ or IHC 2+ with gene amplification on FISH).

View Article and Find Full Text PDF

In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with trastuzumab plus physician's choice chemotherapy (TC) in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall survival (OS) at the median follow-up of 25.8 months.

View Article and Find Full Text PDF

Purpose: To investigate whether hormone receptor-positive, human epidermal growth factor receptor 2-low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characteristics.

Methods: This study included HR+, HER2-negative early breast cancers from patients enrolled in the phase III, randomized BIG 1-98 and SOFT clinical trials that had undergone tumor genomic sequencing. Tumors were classified HR+HER2-low if they had a centrally reviewed HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization and HR+HER2-zero if they had an HER2 IHC score of 0.

View Article and Find Full Text PDF

Purpose: Financial toxicity (FT) has been linked to higher symptom burden and poorer clinical outcomes for patients with cancer. Despite the availability of validated tools to measure FT, a simple screen remains an unmet need. We evaluated item 12 ("My illness has been a financial hardship to my family and me") of the COmprehensive Score for Financial Toxicity (COST) measure as a single-item FT screening measure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!